The ex vivo reversibility of dabigatran-induced whole-blood coagulopathy as monitored by thromboelastography: mechanistic implications for clinical medicine.
Patrick K
PK
Davis
Harsha
H
Musunuru
Mark
M
Walsh
Raman
R
Mitra
Victoria
V
Ploplis
Francis J
FJ
Castellino
D000991:Antithrombins / Q000009:adverse effects* / Q000097:blood / Q000494:pharmacology; D001562:Benzimidazoles / Q000009:adverse effects* / Q000097:blood / Q000494:pharmacology; D001777:Blood Coagulation / Q000187:drug effects; D001779:Blood Coagulation Factors / Q000494:pharmacology; D000069604:Dabigatran; D004353:Drug Evaluation, Preclinical; D016903:Drug Monitoring / Q000379:methods*; D015942:Factor VIIa / Q000494:pharmacology; D005337:Fibrin / Q000096:biosynthesis; D006474:Hemorrhagic Disorders / Q000097:blood / Q000139:chemically induced*; D006801:Humans; D066298:In Vitro Techniques; D019095:Point-of-Care Systems; D011725:Pyridines / Q000009:adverse effects* / Q000097:blood / Q000494:pharmacology; D011994:Recombinant Proteins / Q000494:pharmacology; D013916:Thrombelastography; D013917:Thrombin / Q000037:antagonists & inhibitors; D014914:Whole Blood Coagulation Time
D000991:Antithrombins; D001562:Benzimidazoles; D001779:Blood Coagulation Factors; D011725:Pyridines; D011994:Recombinant Proteins; C025667:prothrombin complex concentrates; D005337:Fibrin; C103587:recombinant FVIIa; D015942:Factor VIIa; D013917:Thrombin; D000069604:Dabigatran